Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: A need for improved modelling to aid decision making

PharmacoEconomics

Volumn 26, Issue 5, 2008, Pages 409-423

  Annemans, Lieven ^a,b,c  

^a GHENT UNIVERSITY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Anastrozole, therapeutic use; Aromatase inhibitors, therapeutic use; Cost effectiveness; Early breast cancer, treatment; Exemestane, therapeutic use; Letrozole, therapeutic use; Tamoxifen, therapeutic use

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; EARLY CANCER; ENDOMETRIUM CANCER; FRACTURE; FRAGILITY FRACTURE; HEART FAILURE; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THEORETICAL MODEL; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MODELS, ECONOMIC; RISK ASSESSMENT;

EID: 42449092417     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826050-00005     Document Type: Review

References (45)

1. Fentiman I. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors. Int J Clin Pract 2006; 60 (6): 689-93
2. Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 2006; 33 (6): 672-80
3. Perez E. Appraising adjuvant aromatase inhibitor therapy. Oncologist 2006; 11 (10): 1058-69
4. Imai H, Kuroi K, Oshumi S, et al. Economic evaluation of the prevention and treatment of breast cancer: present status and open issues. Breast Cancer 2007; 14 (1): 81-7
5. Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics 2006; 24 (3): 215-32
6. Younis T, Rayson D, Dewar R, et al. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for post-menopausal women with breast cancer. Ann Oncol 2007; 18 (2): 293-8
7. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 2006; 14 (9): 917-27
8. Lundkvist J, Wilking N, Holmberg S, et al. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2007; 102 (3): 289-99
9. Risebrough N, Verma S, Trudeau M, et al. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adju vant therapy for postmenopausal women with primary breast cancer. Cancer 2007 Aug 1; 110 (3): 499-508
10. Mansel R, Locker G, Fallowfield L, et al. Cost-effectiveness of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the UK: the 5 year completed treatment analysis of the ATAC trial. Br J Cancer 2007; 97: 152-61
11. Delea T, Karnon J, Smith R, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006; 12 (7): 374-86
12. Delea T, Karnon J, Sofrygin O, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 2007; 7 (8): 608-18
13. El Ouagari K, Karnon J, Delea T, et al. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 2007; 101 (1): 37-49
14. Moeremans K, Annemans L. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: analysis based on the ATAC trial. Int J Gynecol Cancer 2006; 16 Suppl. 2: 576-8
15. Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years vs sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006 Feb; 17 (2): 217-25
16. Hind D, Ward S, De Nigris E, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007; 11 (26): 1-152
17. Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast 2007; 16 (3): 252-61
18. Hillner B. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004; 101: 1311-22
19. Karnon J, Delea T, Johnston SR, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006; 24 (3): 237-50
20. Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 2007 Mar; 101 (3): 325-33
21. Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. Epub 2007 Jun 30
22. Kilian R, Porzolt F. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature. Breast 2005; 14 (6): 636-42
23. Weinstein M, O'Brien B, Hornberger J, et al. ISPOR Task Force on Good Research Practices - Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6 (1): 9-17
24. Locker GY, Mansel R, Cella D, et al., ATAC Trialists' group. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2007 Dec; 106 (2): 229-38
25. Piskur P, Sonc M, Cufer T, et al. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anticancer Drugs 2006 July; 17 (6): 719-24
26. Bos J, Postma M, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23 (7): 639-49
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 May 14-20; 365 (9472): 1687-717
28. Coombes RC, Hall E, Gibson LJ, Intergroup Exemestane Study, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004 Mar 11; 350 (11): 1081-92
29. Thürlimann B, Keshaviah A, Coates AS, Breast International Group (BIG) 1-98 Collaborative Group, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005 Dec 29; 353 (26): 2747-57
30. Goss PE, Ingle JN, Martino S, National Cancer Institute of Canada Clinical Trials Group MA 17, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor. J Clin Oncol 2007 May 20; 25 (15): 2006-11
31. Baum M, Buzdar A, Cuzick J, The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003 Nov 1; 98 (9): 1802-10
32. Forbes JF, Cuzick J, Buzdar A, et al., The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9 (1): 45-53
33. Saphner T, Tormey D, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14 (10): 2738-46
34. Jonat W, Mundhenke C. The FACE trial: letrozole or anastrozole as initial adjuvant therapy? Cancer Invest 2007 Feb; 25 (1): 14-8
35. Buzdar A, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 2006 Feb 1; 12 (3 Pt 2): 1037s-48s
36. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 2005 Sep 7; 97 (17): 1262-71
37. Jonat W, Hilpert F, Kaufmann M. Aromatase inhibitors: a safety comparison. Expert Opin Drug Saf 2007; 6: 165-74
38. Williams C, Brunskill S, Altman D, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006; 10 (34): 1-204
39. Dowsett M, Alfred D, on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial [abstract no. 48]. 29th Annual San Antonio Breast Cancer Symposium; 2006 Dec 14-17. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S21
40. International Society for Pharmacoeconomics and Outcomes Research. Country-specific pharmacoeconomic guidelines [online]. Available from URL: http://www.ispor.org/peguide lines/COUNTRYSPECIFIC.asp [Accessed 2008 Apr 9]
41. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006; 24 (11): 1121-31
42. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequential after tamoxifen? Br J Cancer 2006; 94 (4): 460-4
43. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. The Lancet 2005; 365: 60-2
44. Coates AKA, Thurlimann B, Mouridsen H, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study. J Clin Oncol 2007; 25 (5): 486-92
45. Cianfrocca M, Goldstein L. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9 (6): 606-16